Sign Up
Login
Try for Free
Login
The Epworth Sleepiness Scale (ESS) is an eight-item self-report measure of usual daytime dozing propensity, published by Murray Johns in 1991 and scored 0 to 24. Sleep, respiratory, primary care, and occupational clinicians use it at evaluation and to track treatment. It measures sleepiness; it never diagnoses sleep apnea. This page covers how to document and interpret ESS results in the chart, with a fictional sample note.
Patient self-report (adult ESS); parent or carer assistance for younger children on the ESS-CHAD; scored by any clinician or staff; every use is licensed through Mapi Research Trust
Sleep medicine and respiratory clinics, primary care, PAP suppliers and payers, occupational and driver medical examiners, prescribers of wake-promoting agents
2 to 5 chart lines per administration · patient completion 2 to 3 minutes
Self-report sleepiness measure (eight everyday situations rated 0 to 3, total 0 to 24)
Initial sleep evaluation, pretreatment baseline, PAP and medication follow-up, annual OSA review, driver and occupational fitness assessment, Australia's direct-access sleep-study pathway
Copyright the estate of Murray W. Johns, licensed through Mapi for every use with or without a fee; named in Australia's MBS pathway (8 or more with an OSA-risk screen); mandated by no US or Canadian law
The Epworth Sleepiness Scale is a self-report measure of a person's usual propensity to doze in eight everyday situations, developed by Murray W. Johns at Epworth Hospital in Melbourne and first published in Sleep in 1991, with the current standard adult wording dating from the 1997 revision. Each situation is rated on a four-level scale scored 0 to 3 for the respondent's average tendency to doze in recent times, and the eight ratings sum to a 0 to 24 total; a total with any situation unanswered is invalid and is not imputed. The recall frame is deliberately not a fixed number of days: the official explanation is that "recent times" spans roughly weeks to months so respondents have met most of the situations, and a version that fixes the interval (for treatment comparisons, say) is a specific version requiring permission. The ESS-CHAD, authorized in 2015 for children and adolescents, keeps the eight-situation architecture with developmentally appropriate wording and an explicit recent-month frame.
Three facts govern the documentation. First, the construct is average sleep propensity, not fatigue, not tiredness at the moment of administration, not sleep quality, and not the risk of obstructive sleep apnea; the ESS correlates only weakly with apnea severity and with objective sleepiness tests, so a low score cannot exclude OSA and a high one identifies no cause. Second, the score is a symptom measure with a conventional threshold: on the official interpretation, 0 to 10 is the normal range (0 to 5 lower, 6 to 10 upper), 11 to 12 mild, 13 to 15 moderate, and 16 to 24 severe excessive daytime sleepiness, so 11 is the first elevated score, and policy thresholds such as Australia's 8 or more or a US utilization manager's above 10 are access criteria, not clinical redefinitions. Third, it is licensed intellectual property: the copyright belongs to the estate of Dr Johns, Mapi Research Trust administers licences and authorized translations worldwide, and a licence is required for every use, whether or not a fee is payable. The OSA-risk question belongs to the STOP-Bang, the insomnia question to the Insomnia Severity Index, and Australia's Medicare pathway requires the ESS together with an OSA-risk instrument for exactly that reason.
Sleep medicine and respiratory clinics chart it at the initial evaluation, as the pretreatment baseline, at PAP and medication follow-ups, and at least annually in ongoing OSA care, which is the cadence the American Academy of Sleep Medicine's quality framework describes alongside drowsy-driving assessment and adherence review. Primary care uses it to quantify a sleepiness complaint before referral, PAP suppliers and payers see it in the clinical evaluation that supports testing and in the reevaluation that supports continued coverage, and prescribers of wake-promoting agents meet it on prior-authorization forms that ask for a validated sleepiness scale without, in current policies, a uniform numeric rule. Occupational and driver medical examiners use it as one input in a fitness assessment that turns on actual sleepiness, crash history, and treatment, never on the score alone; the official ESS site itself cautions against using the scale on its own where a legal outcome such as a driving privilege depends on it. The score belongs beside the OSA-risk result on the STOP-Bang page, in the medication management note when a wake-promoting agent is titrated, and in the fitness-for-duty evaluation or return-to-work letter when safety-critical work is the question.
No US, Canadian, or Australian law prescribes an ESS note format, and no authority makes a score diagnostic. What survives review is a dated, patient-reported result with the version, mode, and validity stated, the total written out of 24 with its official band, the sleep-opportunity and medication context that explains it, the safety history, a modest interpretation, and a comparison with the prior score under comparable conditions. Each element below carries the pitfall that most often undermines it.
Version, mode, respondent, and assistance. Chart adult ESS (1997 standard) or ESS-CHAD, the language and whether the translation is authorized, the mode (paper, licensed portal or EHR form, interview, telephone), who answered (patient; parent or carer under ESS-CHAD guidance), and any reading help, interpreter, or partner prompting. Pitfall: "Epworth 14" with no version, mode, or respondent, or a partner-completed adult form charted as if the patient answered it.
The total, out of 24, and its validity. Write x/24 and confirm all eight situations were answered; a total with any missing response is invalid and is not imputed, and a half-point total is rounded up per the official guidance. Note the standard recall frame (recent times) and do not insert a fixed interval into a locally reproduced form. Pitfall: A total scored from seven answers, or a locally edited form with a new recall window that breaks comparability with the norms.
The band, with 10 kept normal. State the official band: 0 to 10 normal (0 to 5 lower, 6 to 10 upper), 11 to 12 mild, 13 to 15 moderate, 16 to 24 severe excessive sleepiness. Above 10 and 11 or more describe the same threshold; a policy using 8 or more (Australia's MBS pathway) or above 10 (a US utilization manager) is an access criterion and the CMS PAP policy appendix's 0 to 9 "normal" is a legacy label, not the rights holder's interpretation. Pitfall: A 10 charted as abnormal, an 8 charted as excessive sleepiness because a payer pathway uses it, or the bands treated as diagnostic categories.
What it does not measure. State that the score reflects reported dozing propensity and identifies no cause: it is not an OSA-risk score, an apnea severity measure, a sleep-quality or insomnia measure, a substitute for polysomnography, home testing, MSLT, or MWT, or a real-time alertness or crash-risk test; a low score does not exclude OSA. Pitfall: "ESS 15, consistent with sleep apnea," or "ESS 6, sleep apnea unlikely," when the ESS-apnea correlation runs about 0.1 to 0.2.
Context that explains the number. Record usual sleep opportunity and recent restriction, shift work or circadian factors, sedating and stimulating medications, alcohol and other substances, caffeine, mood, acute illness, and treatment adherence; then the safety history: dozing while driving or operating equipment, near-misses, crashes, unintentional sleep episodes, and occupational exposure. Collateral goes in separately with its source. Pitfall: An elevated score attributed to OSA in a rotating-shift worker sleeping five hours on a sedating antihistamine, or a low score accepted at face value beside admitted sleep-at-the-wheel episodes.
Change over time, described not over-claimed. Give the prior score, date, and conditions, the absolute change, and whether administration was comparable; group-level minimally important difference estimates in OSA run about 2 to 3 points, but in a short-interval repeatability study 63% of retested patients differed by at least 2 points and 48% by at least 3, so pair the change with objective PAP use and efficacy, function, and safety history before calling it response. Pitfall: "Responded to CPAP, ESS down 2" with no usage data, or worsening blamed on treatment failure before sleep opportunity, schedule, and medication are reviewed.
Plan, follow-up, and the licence. Link the result to the decision: objective testing, medication review, sleep-extension trial, PAP optimization, MWT where wakefulness in safety-sensitive work is the question, driving advice, and the next administration on the same version and mode; and note that the instrument was administered under the practice's licence, with no items reproduced in the note. Pitfall: A number filed with no consequence, or the eight situations pasted into a chart template or an unlicensed EHR form.
EPWORTH SLEEPINESS SCALE DOCUMENTATION BLOCK Date: [ ] Setting: [ ] Clinician: [ ] Time point: [initial / pretreatment baseline / PAP day __ / medication follow-up / annual] Version: [adult ESS 1997 / ESS-CHAD] Language: [ ] Translation: [ ] Mode: [paper / licensed portal or EHR / interview / telephone] Respondent: [patient / parent or carer (ESS-CHAD)] Assistance: [none / reading help / interpreter / prompting] Total: [ ]/24 Validity: [all 8 answered / missing: invalid] Band (official): [0-10 normal (0-5 lower, 6-10 upper) / 11-12 mild / 13-15 moderate / 16-24 severe]; policy thresholds (MBS 8+, payer over 10) are access criteria, not this band Context: [usual sleep opportunity, recent restriction, shift work, sedating or stimulating medications, alcohol, caffeine, mood, illness, treatment adherence] Safety: [dozing while driving or operating equipment, near-misses, crashes, unintentional sleep episodes, occupational exposure] Collateral (separate, with source): [ ] Interpretation: [reported dozing propensity in context; not an OSA-risk score, not a diagnosis, not a driving-fitness determination] Prior: [date] [ ]/24 under [comparable / different] conditions Change: [ ] points; paired with [objective PAP use, function] Plan: [testing / medication review / sleep-extension trial / PAP optimization / MWT / driving advice / next administration + date] Licence: [administered under practice licence; no items in note] Clinician signature / credentials: Date:
Free to use and share, no signup. The PDF includes a one-page cheat sheet with element-by-element pitfalls and a pre-sign checklist; the DOCX is the blank documentation block, ready to adapt. Neither reproduces the scale's situations, response options, or forms.
Scenario: a PAP follow-up inside the Medicare reevaluation window, with a repeat ESS compared to the pretreatment baseline, objective usage and efficacy data alongside the score, the safety history reviewed, and the change described rather than over-claimed. All details are fictional.
Patient: C.D., 47 · Setting: Sleep medicine clinic, PAP follow-up (day 39) · Clinician: H. Brennan, NP · Note date: 08/14/2026
Measure: Epworth Sleepiness Scale, adult 1997 version, English, patient self-completed on paper in the waiting room before the visit; all eight situations answered; no proxy, prompting, or reading assistance. Total 7/24, within the official normal range (upper portion). Baseline at the initial evaluation 07/01/2026, same version, mode, and conditions: 17/24 (severe range). Change: 10 points.
Context: Auto-titrating PAP started 07/06/2026 for moderate OSA on home testing (result and settings documented separately). Device download for the last 30 days: use on 28 of 30 nights, average 6 hours 20 minutes per night, residual event burden low, no significant leak. Usual sleep opportunity now about 7.5 hours; no shift work; no sedating medication; alcohol occasional. Reports waking refreshed most days and no unintentional daytime dozing. Direct inquiry: no sleep-at-the-wheel events, near-misses, or crashes since starting treatment; drove to the visit. Partner's observation of much quieter sleep noted separately as collateral.
Interpretation: Substantial improvement in reported dozing propensity, from the severe range to the normal range, corroborated by objective use above the 4-hour, 70%-of-nights pattern, low residual events, and improved daytime function; the ESS itself does not measure apnea control, and the score is read with the device data rather than as proof of treatment success on its own. Group-level meaningful-change estimates run about 2 to 3 points, and short-interval retest noise can reach several points, which a 10-point change well exceeds.
Plan: Continue PAP at current settings; supplier notified that the clinical reevaluation within the day-31-to-91 window is complete with documented symptom improvement and objective adherence. Mask fit and humidification reviewed. Counseled to avoid driving when sleepy and to report any return of dozing. Repeat ESS on the same version and mode at the annual review, or sooner if symptoms change; annual drowsy-driving and adherence review scheduled.
Administrative: Score, version, mode, band, baseline, and change entered in the sleep flowsheet; usage report filed. Instrument administered under the clinic's licence through Mapi Research Trust; no scale items reproduced in the record.
This sample is fictional and for educational purposes. It does not describe a real patient or record; the scores, dates, and details are invented to show documentation structure and are not clinical guidance.
Writing these after every session? BastionGPT drafts complete notes from bullets, dictation, or a transcript.
Generate a note from bulletsUnited States: payer policies use the score in different ways, and no law names it. Carelon's sleep-disorder management guideline (effective November 2025, codes updated July 2026, a new edition scheduled for 19 September 2026) accepts an ESS above 10 as one way to document excessive daytime sleepiness in a sleep-study pathway that ordinarily needs a combination of clinical criteria (PAYER POLICY); Medicare's sleep-testing and PAP policies recognize documented excessive sleepiness as a symptom that can support coverage without requiring a score or a numeric threshold, and its PAP local coverage determination reproduces the scale in an appendix (with a legacy permission line and a 0 to 9 "normal" label that conflicts with the rights holder's 0 to 10) while conditioning continued coverage on a clinical reevaluation between day 31 and day 91, documented symptom improvement, and objective use of at least 4 hours a night on 70% of nights in a consecutive 30-day period within the first three months, not on the ESS falling below 11 (PAYER POLICY). Current modafinil and armodafinil prior-authorization policies reviewed (CVS Caremark, Cigna, Aetna Better Health, Highmark, Anthem) ask for diagnosis, objective criteria, exclusion of insufficient sleep, adequate PAP treatment, and clinical response, or for a validated sleepiness scale, without a uniform numeric ESS rule; the archived policies that used 10 explain the memory of a required Epworth and should not be generalized (PAYER POLICY). For commercial drivers, 49 CFR 391.41(b)(5) bars a respiratory dysfunction likely to interfere with safe driving and names no OSA test or ESS (LAW); FMCSA's 2024 handbook states its regulations prescribe no screening method, referral rule, testing, treatment, or compliance threshold (CONVENTION), and the Medicare 4-hour, 70% pattern is not a federal driver-certification standard. FAA aviation materials (May 2026) treat untreated or poorly controlled OSA as potentially disqualifying, set no ESS number, and use a stricter PAP expectation of treatment during at least 75% of sleep periods averaging at least six hours (CONVENTION), so an occupational note names the applicable protocol rather than importing the Medicare minimum. Narcolepsy and idiopathic hypersomnia workups (CONVENTION) require adequate sleep documented by diary and often actigraphy, other sleep disorders stabilized, and PSG with MSLT; the ESS quantifies reported sleepiness and supplies no diagnostic threshold, and the AASM's quality framework calls for sleepiness assessment at initial evaluation and at least annually in treatment.
Canada, Australia, and the evidence. Canada's June 2026 CCMTA driver-fitness model standard (CONVENTION, applied through provincial licensing LAW) treats the ESS as subjective, sets no numeric cutoff, decides on disease severity, admitted sleepiness, sleepiness-related crashes, treatment effectiveness, and ongoing commercial review, and contains a primary-source error worth knowing: it describes the response scale as 1 to 4 where the authorized architecture is 0 to 3, so its description should not be copied into local forms; British Columbia, Ontario, and Quebec run their own reporting duties and medical forms with no ESS trigger. Australia's Austroads standard (2022, CONVENTION applied through state LAW) states that the ESS is neither sensitive nor specific for diagnosing OSA, depends on honest reporting, and is one component of assessment; state and territory notification duties turn on impairment, not a total. Australia's Medicare direct-access adult sleep-study pathway (items 12203 and 12250, PAYER POLICY) requires an ESS of 8 or more together with a STOP-Bang of 3 or more, an OSA50 of 5 or more, or a high-risk Berlin, with the complete questionnaires, responses, and scores retained for audit, and the PBS narcolepsy authority criteria for wake-promoting agents reference objective testing rather than an ESS score. On the evidence: the 1992 reliability study found five-month test-retest correlation 0.82 and alpha 0.88 in medical students; a 2014 systematic review of 35 studies found internal consistency about 0.73 to 0.86 and pooled correlations of about minus 0.43 with the MWT, minus 0.27 with the MSLT, and 0.11 to 0.23 with sleep-apnea measures, judging the evidence better for group comparison than precise individual inference; OSA trial analyses estimate a minimally important difference near 2 points (639 participants) and 2 to 3 points, while a short-interval repeatability study of 40 sleep-clinic patients found retest differences of at least 2 points in 63%, 3 in 48%, 5 in 20%, and 7 in 8%; and when 122 patients were told about licensing implications, the group mean did not change but about 9% crossed the sleepy-versus-not classification, which supports caution about threshold-based legal decisions without assuming every low score is dishonest. Normative work varies by country: 507 Australian workers without a sleep disorder averaged 4.6 with 10.9% of the whole sample above 10, a US community sample of 703 adults showed little effect of age or sex, and a German population sample of 9,711 found about 23% above 10, so scores are recorded as standard totals and read in context, not age-adjusted informally.
Rights are broader than most pages say. The copyright in the Epworth Sleepiness Scale and the ESS-CHAD belongs to the estate of Dr Murray W. Johns (who died in 2021), and Mapi Research Trust administers usage, licences, and authorized translations worldwide through its ePROVIDE platform. The official position, as stated in August 2026, is that a licence is required for every use, whether or not a licence fee is payable: students, physicians in individual clinical practice, and non-funded academic users may register for direct access, funded academic projects, healthcare organizations, commercial users, and IT companies submit a request and fees may apply, electronic implementations require an agreement for all user classes with implementation and screenshot review, and no universal price list is published because fees are quoted by project, language, and scope. Printing the form into an intake packet, scanning it into a forms library, building it into an EHR flowsheet, portal, app, or decision-support rule, or hosting a free public calculator are all reproduction or electronic use, and neither wide online circulation nor an older permission footnote (Austroads' note that individual doctors may use it without permission describes past practice) changes the current terms; documenting a result such as "ESS 14/24" is different from reproducing the instrument. The Epworth Sleepiness Scale is copyright of the estate of Dr Murray W. Johns and licensed worldwide through Mapi Research Trust. BastionGPT is not affiliated with, or endorsed by, the Johns estate or Mapi Research Trust. This page reproduces none of the scale's situations, response options, or forms and describes the instrument in original prose.
The numbers behind these errors are specific. The ESS correlates about 0.11 to 0.23 with sleep-apnea measures and minus 0.27 with the MSLT across 35 studies; the official normal range is 0 to 10 while a Medicare policy appendix labels 0 to 9 normal and Australia's pathway uses 8 or more; group-level meaningful change is about 2 to 3 points while 63% of retested patients differed by at least 2 points over a short interval; and every use requires a licence whether or not a fee is payable. The BastionGPT Clinical Advisory Board sees the same errors most often in ESS documentation reviews:
BastionGPT is specifically trained, tuned, and clinically tested on behavioral health progress notes and screening documentation.
See how clinicians use it day to day on the AI therapy notes page.
Many BastionGPT users report saving more than 90 minutes per day on documentation.
HIPAA-compliant with a signed BAA on every plan. Your data is never used to train models. BastionGPT drafts, you review and sign.
Eight everyday situations are each rated 0 to 3 for the respondent's usual chance of dozing in recent times, and the ratings sum to a total of 0 to 24; a total with any situation unanswered is invalid and is not imputed, and a half-point total is rounded up. On the official interpretation, 0 to 10 is the normal range (0 to 5 lower, 6 to 10 upper), 11 to 12 mild, 13 to 15 moderate, and 16 to 24 severe excessive daytime sleepiness, so above 10 and 11 or more describe the same conventional threshold. The bands describe reported dozing propensity, not a diagnosis and not a cause: an elevated score is compatible with insufficient sleep, shift work, sedating medication, depression, sleep-disordered breathing, central disorders of hypersomnolence, or several of these together, and the differential lives in the note, not in the number.
Normal, on the current official interpretation: 0 to 10 is the normal range and 11 is the first elevated score. Three sources make clinicians unsure. Australia's Medicare direct-access sleep-study pathway uses 8 or more, but only combined with a separate OSA-risk instrument, as an access criterion, not a redefinition of abnormal sleepiness; a US utilization manager's pathway uses above 10, which is the same boundary as 11 or more; and the Medicare PAP policy appendix labels 0 to 9 as normal, a legacy label that is neither the rights holder's interpretation nor a coverage threshold. Historically the author suggested 16 in 1991 and above 9 in 1992 before the modern above-10 convention settled. Chart the official band and, where a policy threshold matters, name the policy.
Neither. The ESS measures average sleep propensity, and across 35 studies its correlation with sleep-apnea measures ran about 0.11 to 0.23; the American Academy of Sleep Medicine's guideline says questionnaires must not be used to diagnose OSA without polysomnography or technically adequate home testing, and Australia's Austroads standard says the ESS is neither sensitive nor specific for OSA. A high score raises the question of cause (insufficient sleep, circadian misalignment, sedating drugs, mood, sleep-disordered breathing, hypersomnolence disorders); a low score can reflect limited awareness of dozing, fatigue without recognized dozing, adaptation, strategic reporting, or an OSA phenotype without much subjective sleepiness. "My doctor says a low Epworth proves I don't have sleep apnea" is a common patient report and it is wrong; testing decisions use the full history, examination, the STOP-Bang or another risk screen, and objective testing criteria.
Only under a licence. The copyright belongs to the estate of Dr Murray W. Johns and Mapi Research Trust administers it worldwide; the official position is that a licence is required for every use, whether or not a licence fee is payable. Students, physicians in individual clinical practice, and non-funded academic users may register for direct access; funded academic projects, healthcare organizations, commercial users, and IT companies submit a request and fees may apply; electronic implementations (an EHR flowsheet, portal questionnaire, app, REDCap build, or vendor scoring component) require an agreement for all user classes with implementation and screenshot review; and there is no public price list because fees are quoted per project, language, and scope. A free public calculator on a commercial site is reproduction and public display, not an exemption. Documenting "ESS 14/24" is different from reproducing the eight situations, and the widespread online copies, government-hosted appendices, and older permission footnotes prove circulation, not permission. Terms as stated on the official ESS and Mapi pages in August 2026.
No. The current Medicare PAP local coverage determination conditions continued coverage on a clinical reevaluation no earlier than day 31 and no later than day 91 after initiation, documentation that OSA symptoms have improved, and objective use of at least 4 hours a night on 70% of nights in a consecutive 30-day period within the first three months; it does not require the ESS to fall below 11 or improve by any number of points, and its appendix's 0 to 9 "normal" label is not a coverage threshold. Medicare's sleep-testing policy likewise recognizes documented excessive sleepiness as a supporting symptom without a score. Among commercial payers, one utilization manager accepts an ESS above 10 as one route to document sleepiness in a pathway that generally needs a combination of criteria; wake-promoting-agent prior authorizations ask for diagnosis, objective findings, adequate PAP, and clinical response, or a validated sleepiness scale, without a uniform numeric ESS rule in current policies. The reevaluation visit is a sensible time to repeat the ESS, paired with the usage download, but the download and the symptom statement are what the policy reads.
No authority reviewed sets an ESS number as a licensing or certification rule. The US federal standard for commercial drivers (49 CFR 391.41(b)(5)) bars a respiratory dysfunction likely to interfere with safe driving and names no OSA test or score, and FMCSA's 2024 handbook states its regulations prescribe no screening method, referral rule, testing, treatment, or compliance threshold; the FAA's May 2026 OSA materials treat untreated or poorly controlled OSA as potentially disqualifying, set no ESS cutoff, and use a PAP expectation of at least 75% of sleep periods averaging at least six hours, stricter than the Medicare coverage minimum. Canada's June 2026 CCMTA model standard treats the ESS as subjective and decides on severity, admitted sleepiness, crashes, and treatment (and, oddly, misdescribes the response scale as 1 to 4); provincial reporting duties turn on impairment, not a total. Australia's Austroads standard says the ESS depends on honest reporting and is one component of assessment, with state notification duties keyed to impairment. Chart the score, the direct safety inquiry, and the individualized reasoning under the applicable rule, and where wakefulness in safety-sensitive work is the question consider objective testing such as the MWT.
Describe the change; do not over-claim it. OSA trial analyses estimate a group-level minimally important difference of about 2 points (639 participants across three trials) and 2 to 3 points, but in a short-interval repeatability study of 40 sleep-clinic patients, sequential scores differed by at least 2 points in 63%, 3 in 48%, 5 in 20%, and 7 in 8%, with a standard error near 2 points, so a 2-point change is meaningful in a group and unproven in an individual. Write "ESS decreased by 3 points" (factual) and "within published group-level estimates of meaningful change" (defensible), and rest a response claim on objective PAP use and efficacy, function, and safety history together; review sleep opportunity, schedule, and medication before calling a rise treatment failure. There is no ESS-only interval: a pretreatment baseline, an early follow-up when adherence and efficacy are reviewed (the Medicare day-31-to-91 window is a natural point), a repeat at meaningful changes in symptoms, schedule, medication, or treatment, and at least annually in ongoing OSA care per the AASM quality framework, always on the same version and mode.
Record the patient's own score exactly and label it self-report; never substitute the clinician's estimate or edit answers to match the impression. Chart inconsistencies factually (a low ESS beside acknowledged sleep-at-the-wheel episodes), obtain collateral separately with its source, ask directly about involuntary sleep, near-misses, crashes, work incidents, and countermeasures, review sleep duration, schedule, medications, substances, and treatment data, and consider objective testing such as the MWT when the question is ability to stay awake in a safety-sensitive setting; then apply the jurisdiction's actual reporting law, which turns on impairment or danger, not a number. When 122 patients were told about licensing implications the group mean did not change but about 9% crossed the classification boundary, so the concern is real without every low score being dishonest. The adult ESS is patient-reported: a partner may help with reading or comprehension if that is documented, partner observations go in as collateral, and a proxy score is labelled as such and kept separate; the ESS-CHAD expressly allows more parent or carer involvement for younger children.
Yes. Give it the facts (version and mode, respondent and assistance, total and validity, sleep opportunity, schedule, medications and substances, safety history, prior score and date, device data, and the plan) and it drafts the full entry: the score out of 24 with its official band, the context and safety lines, a modest interpretation, the change described against the prior result with the objective data beside it, and the plan with the next administration dated, ready for your review. It can also check a finished note for a score charted as an apnea finding, a 10 called abnormal, a total with no version or respondent, response declared from a 2-point change with no usage data, and a safety history never asked, and it never needs the scale's items to do so. BastionGPT is HIPAA-compliant with a signed BAA on every plan, and your data is never used to train models.
The instrument facts and compliance claims on this page trace to these sources, last verified August 2026:
Educational content, not legal or billing advice. Sample notes are fictional. Follow your organization's policies and your board, payer, and jurisdiction requirements.